Research progress of male osteoporotic fracture

Source:
By:晓辉 晓 白

DOI:

Abstract:

Abstract: the diagnosis and recognition of male osteoporosis is still insufficient. The male patients with low-energy fracture were less evaluated and treated for osteoporosis. The risk of osteoporotic fracture in elderly men may be between 13% and 25%. With the extension of men's life, the risk of fracture increases, which makes the management of men with fracture risk challenging. A consensus is emerging on targeted treatment guidelines for male osteoporosis, especially for elderly patients with high fracture risk. This paper aims to seek evidence through literature review, and put forward the most effective clinical strategies and schemes for the diagnosis and treatment of senile osteoporosis, so as to provide some theoretical guidance for clinical practice. 

References:

[1] Solomon DH, Johnston SS, Boytsov NN, et al.Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011[J].Bone Miner Res2014;29:1929-1937. [2] Tory HO, Solomon DH, Desai SP. Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis. Sem Arthritis Rheum 2015;44:483-8. [3] Hopkins RB, Pullenayegum E, Goeree R, et al. Estimation of the lifetime risk of hip fracture for women and men in Canada[J].Osteoporos Int2012;23:921-927. [4]Ettinger B, Ensrud KE, Blackwell T, et al. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study[J].Osteoporos Int 2013;24:1185-1193. [5] Harman SM, Metter EJ, Tobin JD, et al.Longitudinal effects of aging on serum total and free testosterone levels in healthy men[J].Clin Endocrinol Metab 2001;86:724-31 [6] Adler RA. Osteoporosis in men: insights for the clinician[J].Ther Adv Musculoskel Dis 2011;3:191-200. [7] Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study[J].BMJ 2017;357-1415. [8] Orwoll E, Ettinger M, Weiss S, et al. lendronate for the treatment of osteoporosis in men[J].N Engl J Med 2000;343:604-10. [9] Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis[J].N Engl J Med 2012;367:1714-23. [10] Khosla S, Burr D, Cauley J,et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J].Bone Miner Res 2007;22:1479-1491. [11] Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research[J].Bone Miner Res 2014;29:1-23. [12] Langdahl B, Teglbjaerg CS, Ho PR, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial[J].Clin Endocrinol Metab 2015;100:1335-1342. [13] Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide (human parathyroid hormone 1-34) therapy on bone density in men with osteoporosis[J].Bone Miner Res 2003;18:9-17. [14] Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8. [15] Mazanec DJ, Podichetty VK, Mompoint A, et al. Vertebral compression fractures: manage aggressively to prevent sequelae[J].Cleve Clin J Med. 2003 Feb;70(2):147-156. [16] Lou S, Shi X, Zhang X,et al. Percutaneous vertebroplasty versus non-operative treatment for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials[J]. Osteoporos Int.2019Dec;30(12):2369-2380.